Jaka jest cena za Celyad Oncology S.A. (CYAD)

Cena za Celyad Oncology S.A. (CYAD) wynosi $0.343985

Jaka jest kapitalizacja rynkowa dla Celyad Oncology S.A. (CYAD)

Kapitalizacja rynkowa dla Celyad Oncology S.A. (CYAD) wynosi $15.40M

Celyad Oncology S.A. (CYAD) Stopa Dywidendy

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.

Rok	Stopa dywidendy	Zmień
Za mało danych dla podanych dat.

Rok

Stopa dywidendy

Zmień

Za mało danych dla podanych dat.

Firma	Stopa dywidendy	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH
UCB S.A. UCB.BR	0.48%	BE

Firma

Stopa dywidendy

Kraj

Vertex Pharmaceuticals Incorporated

VRTX.US

0.00%

Argenx SE

ARGX.US

0.00%

CSL Limited

CSL.AX

3.12%

Lonza Group AG

LONN.SW

0.00%

UCB S.A.

UCB.BR

0.48%

Celyad Oncology S.A.

CYAD

Kategoria